Please enable JavaScript.
Coggle requires JavaScript to display documents.
T2DM, https://cks.nice.org.uk/topics/diabetes-type-2/ - Coggle Diagram
T2DM
-
-
ANTIDIABETC DRUGS
OFFER STANDARD RELEASE METFORMIN AS FIRST-LINE TREATMENT, UNLESS CONTRAINDICTAED
Gradually increase the dose of standard-release metformin over several weeks to minimize the risk of adverse effects.
If there are intolerable gastrointestinal adverse effects, consider a trial of modified-release metformin.
-
-
Established atherosclerotic cardiovascular disease or high risk of developing cardiovascular disease
BASED ON CARDIOVASCULAR RISK ASSESSMENT:
If chronic heart failure or established atherosclerotic cardiovascular disease, offer an SGLT-2 inhibitor with proven cardiovascular benefit in addition to metformin
If high risk of developing cardiovascular disease, consider an SGLT-2 inhibitor with proven cardiovascular benefit in addition to metformin
-
-
DEFINITION:
A metabolic disorder resulting in persistent hyperglycaemia due to insulin resistance and a relative insulin deficiency
-